Low-density lipoprotein cholesterol reduction by inhibition of PCSK9

Current Opinion in Lipidology

Volumn 24, Issue 6, 2013, Pages 510-517

  Stein, Evan A ^a  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

LDL cholesterol; monoclonal antibodies; proprotein convertase subtilisin kexin type 9

Indexed keywords

ALIROCUMAB; ATORVASTATIN; BMS 962476; EVOLOCUMAB; EZETIMIBE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPOCHOLESTEROLEMIC AGENT; KEXIN; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN RECEPTOR; LY 3015014; MONOCLONAL ANTIBODY; PF 0490615; PF 04950615; PREDNISONE; PROPROTEIN CONVERTASE 1; PROTEIN PCSK9; RG 7652; RN 316; SERINE PROTEINASE; SMALL INTERFERING RNA; SUBTILISIN; UNCLASSIFIED DRUG;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DIET THERAPY; DRUG DOSE INCREASE; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENZYME INHIBITION; FAMILIAL HYPERCHOLESTEROLEMIA; HUMAN; HYPERCHOLESTEROLEMIA; INJECTION SITE REACTION; LEUKOCYTOCLASTIC VASCULITIS; MUSCLE DISEASE; MYALGIA; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; TREATMENT DURATION;

ANIMALS; ANTICHOLESTEREMIC AGENTS; CHOLESTEROL, LDL; CLINICAL TRIALS AS TOPIC; HUMANS; SERINE ENDOPEPTIDASES; SERINE PROTEINASE INHIBITORS;

EID: 84888294490     PISSN: 09579672     EISSN: 14736535     Source Type: Journal    
DOI: 10.1097/MOL.0000000000000021     Document Type: Review

References (18)

1. Stein EA. Swergold GD potential of proprotein convertase subtilisin/kexin type 9 based therapeutics. Curr Atheroscler Rep 2013; 15:310
2. Lambert G, Sjouke B, Choque B, et al. The PCSK9 decade. J Lipid Res 2012; 53:2515-2524.
3. Stein EA, Mellis S, Yancopoulos GD, et al. Effect of a monoclonal antibody to PCSK9 on LDL cholesterol. N Engl J Med 2012; 366:1108-1118
4. Regeneron Pharmaceuticals, Inc. Sanofi and Regeneron launch comprehensive phase 3 clinical program with LDL cholesterol-lowering PCSK9 antibody. http://investor.regeneron.com/releasedetail.cfm?ReleaseID-693585 (2012) [Accessed 7 July 2013].
5. Amgen 145 phase3 trials. http://www.clinicaltrials.gov/ct2/results?term- amg+145&recr-Open. [Accessed 7 July 2013]
6. Anti-PCSK9 (MPSK3169A, RG7652) is a monoclonal antibody directed against PCSK9 (proprotein convertase subtilisin/kexin15151. Anti-PCSK9 (MPSK3169A, RG7652) is a monoclonal antibody directed against PCSK9 (proprotein convertase subtilisin/kexin type 9) http://www.gene.com/ medical-professionals/pipeline and http://www.clinicaltrials.gov/ct2/show/ NCT01609140?term-MPSK3169A&rank-1. [Accessed 7 July 2013]
7. Gumbiner B, Joh T, Udata C, et al. Effects of 12 weeks of treatment with RN316 (PF-04950615), a humanized IgG2Da monoclonal antibody binding proprotein convertase subtilisin kexin type 9, in hypercholesterolemic subjects on high- and maximal-dose statins. Circulation 2012; 126:A13524; http://circ.ahajournals. org/cgi/content/meeting
8. LY- 3015014 http://www.clinicaltrials.gov/ct2/results?term-LY3015014 Search-Search. [Accessed 7 July 2013]
9. Single Ascending Dose Safety Study of BMS-962476 in Healthy Subjects and Patients With Elevated Cholesterol on Statins. http://clinicaltrials.gov/ ct2/show/NCT01587365?term-BMS-962476&rank-1. [Accessed 7 July 2013]
10. The Medicines Company and Alnylam Form Strategic Alliance to Develop and Commercialize RNAi Therapeutics Targeting PCSK9 for the Treatment of Hypercholesterolemia. http://ir.themedicinescompany.com/phoenix.zhtml? c-122204&p-irol-newsArticle&ID-1783867&highlight-. [Accessed 7 July 2013]
11. Dias CS, Shaywitz AJ, Wasserman SM, et al. Effects of AMG 145 on lowdensity lipoprotein cholesterol levels: Results from 2 randomized, double-blind, placebo-controlled, ascending-dose phase 1 studies in healthy volunteers and hypercholesterolemic subjects on statins. J Am Coll Cardiol 2012; 60:1888-1898.
12. McKenney JM, Koren MJ, Kereiakes DJ, et al. Safety and efficacy of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease, SAR236553/REGN727, in patients with primary hypercholesterolemia receiving ongoing stable atorvastatin therapy. J Am Coll Cardiol 2012; 59:2344-2353
13. Stein EA, Gipe D, Bergeron J, et al. Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: A phase 2 randomised controlled trial. Lancet 2012; 380:29-36
14. Roth EM, McKenney JM, Hanotin C, et al. Atorvastatin with or without an antibody to PCSK9 in primary hypercholesterolemia. N Engl J Med 2012; 367:1891-1900
15. Raal F, Scott R, Somaratne R, et al. Low-density lipoprotein cholesterol- lowering effects of AMG 145, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease in patients with heterozygous familial hypercholesterolemia: The reduction of LDL-C with PCSK9 inhibition in heterozygous familial hypercholesterolemia disorder (RUTHERFORD) randomized trial. Circulation 2012; 126:2408-2417
16. Sullivan D, Olsson AG, Scott R, et al. Effect of AMG 145, a monoclonal antibody to PCSK9, on LDL cholesterol levels in statin-intolerant patients: The GAUSS randomized trial. JAMA 2012; 308:2497-2506
17. Koren MJ, Scott R, Kim JB, et al. Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 as monotherapy in patients with hypercholesterolaemia (MENDEL): A randomised, double-blind,placebo-controlled, phase 2 study. Lancet 2012; 380:1995-2006.
18. Giugliano RP, Desai NR, Huang F, et al., LAPLACE-TIMI 57 Investigators. Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 in combination with a statin in patients with hypercholesterolaemia (LAPLACE-TIMI 57): A randomised, placebocontrolled,dose- ranging, phase 2 study. Lancet 2012; 380:2007-2017.